Join us on 5th of November for our autumn hybrid event in London. This event will consist of an in-person seminar in London, which will also be streamed live (and recorded), allowing members to watch virtually.
Please register to attend the event in-person or to watch virtually, using the 2 different links below.
Each company will present for 20 minutes and then take your questions for another 10 minutes. All attendees (whether attending in-person or virtually) will be able to ask questions.
Event registration opens at 5.00 pm, and presentations commence at 5.30 pm.
There will be a Networking with light buffet and wine after the presentations.
In-person event is Exclusive to Full ShareSoc and Combined (ShareSoc & SIGnet) members
ShareSoc AGM will be held before the seminar, from 4pm, and invitations will go out to eligible members in the middle of October.
Click here to register for the in-person seminar in London.
Click here to join the virtual event.
Companies Presenting
Bioventix (BVXP)
Bioventix creates, manufactures and supplies high affinity sheep monoclonal antibodies (SMAs) for use in diagnostic applications. Bioventix antibodies are preferred for use when they confer an improved test performance compared to other available antibodies.
Most of Bioventix’s antibodies are used on blood-testing machines installed in hospitals and other laboratories around the world. Bioventix makes antibodies using its SMA technology for supply to diagnostic companies for subsequent manufacture into reagent packs used on blood-testing machines. These blood-testing machines are supplied by large multinational in vitro diagnostics (IVD) companies such as Roche Diagnostics, Siemens Healthineers, Abbott Diagnostics & Beckman Coulter. Antibody-based blood tests are used to help diagnose many different conditions including, amongst others, heart disease, thyroid function, fertility, infectious disease and cancer.
Presenter:
Peter Harrison – CEO
Peter is 66 years old and has over 30 years’ experience of antibody technology at Celltech, KS Biomedix & Bioventix.
Odyssean Investment Trust plc (OIT)
Odyssean Investment Trust is a UK investment company whose shares are traded on the London Stock Exchange. Its investment objective is to achieve attractive total returns per share principally through capital growth over a longer-term period.
It has been managed since its 2018 IPO by Odyssean Capital LLP, an award-winning boutique fund manager, which focuses on investing in smaller quoted companies. OIT’s investment strategy is to manage a concentrated portfolio of small- and mid-cap companies that the Portfolio Manager identifies as undervalued, where it has identified scope for “self-help” to drive shareholder returns. The Portfolio Manager takes an engaged, long-term ownership approach to support portfolio companies to undertake strategic, operational, and/or governance improvements.
Presenter:
Edward Wielechowski, Partner
Edward is a Fund Manager at Odyssean Capital LLP in London, where he has worked since December 2017. He focuses on investing in small to mid-sized companies across both public and private markets, bringing a private equity philosophy to public market investments. As portfolio manager for the Odyssean Investment Trust, he co-manages a concentrated portfolio of well-researched UK smaller companies, typically outside the FTSE 250, aiming to deliver 15% annualised returns over five years by targeting businesses with transformation potential trading below intrinsic value. His approach emphasises mid- to long-term holding, quality assessment, and disciplined focus on £100m–£1bn market cap companies, differentiating from pure growth or value strategies.
Third Company – to be announced soon
Keynote Speaker
Lord Lee of Trafford – John Lee
Presentation topic: British Share Bargains: Buying £1 of Assets for 50p
John Lee is regarded as one of the UK’s leading private investors, having bought his first shares sixty years ago. He was one of the earliest to recognise the long-term potential of PEPs (the forerunner of ISAs) when they were launched in 1987 and was judged to be the first ISA millionaire in 2003.
John has written over 250 articles for FT Money and has given numerous lectures and interviews on his investment philosophy as a long-term value investor. John is a Chartered Accountant with a wide experience of investment banking and business and is Patron of ShareSoc.